FEB 27, 2019 3:00 PM PST

Targeted Cancer Chemotherapy: Developing NextGen Antibody-Drug Conjugates

Presented at: Drug Discovery 2019
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Senior Vice President, Research & Development, ModMab Therapeutics, Inc.
    Biography
      Over 15 years of experience in oncology drug discovery and development/antibody therapeutics and more than 20 years of experience in the life science research as a biochemist/molecular cell biologist. Recognized in the scientific and pharmaceutical communities for inventing and developing a novel and innovative THIOMAB technology platform to obtain engineered ADCs with defined number of payloads per conjugate. Authored over 100 patents/peer-reviewed publications and have been a featured keynote speaker at many international high-profile scientific conferences. Led cross-functional teams in the discovery of innovative Antibody Dug Conjugates (ADCs) and Bi-specific cancer immunotherapeutic programs. Core member of launched T-DM1 (Kadcyla) R&D team. Led the teams, which discovered and developed a next generation site-specific T-DM1 ADC project and over 10 other ADC/Bi-specific antibody therapeutic candidates. Leveraged several cross-functional teams in discovery research, pre-clinical research and manufacturing to move antibody based therapeutic molecules from discovery to IND.

    Abstract

    In today's presentation I will give an overview to developing NextGen ADCs. We will discuss everything from the beginning stages of development to the varying ADC combination therapies available. (There are currently 23 ADCs in total being studied in 45 combination trials with 10 different  immune checkpoint modulators).

    Learning Objectives: 

    1. This presentation will discuss past, present challenges associated with developing antibody-drug conjugates (ADCs), a novel modality of targeted cancer chemotherapy
    2. Presentation will also highlight key factors that influence in developing next generation ADCs. 


    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    NOV 18, 2019 7:00 AM PST
    C.E. CREDITS
    NOV 18, 2019 7:00 AM PST
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    MAY 08, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    MAR 24, 2020 10:00 AM PDT
    C.E. CREDITS
    MAR 24, 2020 10:00 AM PDT
    DATE: March 24, 2020 TIME: 10:00 am PDT, 1:00pm EDT The Clampfit software module is a useful tool to manipulate and analyze electrophysiological data acquired by pCLAMP™ software. Rece...
    Loading Comments...
    Show Resources